http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 07 Aug 2026 08:59:15 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Earnings/Atossa+Genetics+%28ATOS%29+Tops+Q2+EPS+by+10c/26888255.html <p>Atossa Genetics (NASDAQ: ATOS) reported Q2 EPS of ($0.95), $0.10 better than the analyst estimate of ($1.05).</p><p>For earnings history and earnings-related data on Atossa Genetics (ATOS) <a href="http://www.streetinsider.com/ec_earnings.php?q=ATOS">click here</a>.</p> http://www.streetinsider.com/Earnings/Atossa+Genetics+%28ATOS%29+Tops+Q2+EPS+by+10c/26888255.html Fri, 07 Aug 2026 08:59:15 -0400 ATOS http://www.streetinsider.com/Press+Releases/Atossa+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+a+Corporate+Update/26888131.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.wa.seatle" idsrc="xmltag.org" >SEATTLE</location></span>, <span class="legendSpanClass"><chron>Aug. 7, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-SMALL:ATOS" idsrc="xmltag.org" >Atossa Therapeutics, Inc.</span> (Nasdaq: ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet clinical need, today announced its financial results and provided an update on recent corporate developments for the second quarter ended <chron>June 30, 2026</chron>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Atossa+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+a+Corporate+Update/26888131.html Fri, 07 Aug 2026 08:45:00 -0400 A.06822034 A.50216726 ATOS O.11433789 O.20026344 O.21612337 http://www.streetinsider.com/Press+Releases/Atossa+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+a+Corporate+Update/26888131.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.wa.seatle" idsrc="xmltag.org" >SEATTLE</location></span>, <span class="legendSpanClass"><chron>Aug. 7, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-SMALL:ATOS" idsrc="xmltag.org" >Atossa Therapeutics, Inc.</span> (Nasdaq: ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet clinical need, today announced its financial results and provided an update on recent corporate developments for the second quarter ended <chron>June 30, 2026</chron>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Atossa+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+a+Corporate+Update/26888131.html Fri, 07 Aug 2026 08:45:00 -0400 A.06822034 A.50216726 ATOS O.11433789 O.20026344 O.21612337 http://www.streetinsider.com/Press+Releases/Atossa+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+a+Corporate+Update/26888131.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.wa.seatle" idsrc="xmltag.org" >SEATTLE</location></span>, <span class="legendSpanClass"><chron>Aug. 7, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-SMALL:ATOS" idsrc="xmltag.org" >Atossa Therapeutics, Inc.</span> (Nasdaq: ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet clinical need, today announced its financial results and provided an update on recent corporate developments for the second quarter ended <chron>June 30, 2026</chron>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Atossa+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+a+Corporate+Update/26888131.html Fri, 07 Aug 2026 08:45:00 -0400 A.06822034 A.50216726 ATOS O.11433789 O.20026344 O.21612337 http://www.streetinsider.com/Press+Releases/Atossa+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+a+Corporate+Update/26888131.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.wa.seatle" idsrc="xmltag.org" >SEATTLE</location></span>, <span class="legendSpanClass"><chron>Aug. 7, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-SMALL:ATOS" idsrc="xmltag.org" >Atossa Therapeutics, Inc.</span> (Nasdaq: ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet clinical need, today announced its financial results and provided an update on recent corporate developments for the second quarter ended <chron>June 30, 2026</chron>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Atossa+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+a+Corporate+Update/26888131.html Fri, 07 Aug 2026 08:45:00 -0400 A.06822034 A.50216726 ATOS O.11433789 O.20026344 O.21612337 http://www.streetinsider.com/Press+Releases/Atossa+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+a+Corporate+Update/26888131.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.wa.seatle" idsrc="xmltag.org" >SEATTLE</location></span>, <span class="legendSpanClass"><chron>Aug. 7, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-SMALL:ATOS" idsrc="xmltag.org" >Atossa Therapeutics, Inc.</span> (Nasdaq: ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet clinical need, today announced its financial results and provided an update on recent corporate developments for the second quarter ended <chron>June 30, 2026</chron>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Atossa+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+a+Corporate+Update/26888131.html Fri, 07 Aug 2026 08:45:00 -0400 A.06822034 A.50216726 ATOS O.11433789 O.20026344 O.21612337 http://www.streetinsider.com/Press+Releases/Atossa+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+a+Corporate+Update/26888131.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.wa.seatle" idsrc="xmltag.org" >SEATTLE</location></span>, <span class="legendSpanClass"><chron>Aug. 7, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-SMALL:ATOS" idsrc="xmltag.org" >Atossa Therapeutics, Inc.</span> (Nasdaq: ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet clinical need, today announced its financial results and provided an update on recent corporate developments for the second quarter ended <chron>June 30, 2026</chron>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Atossa+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+a+Corporate+Update/26888131.html Fri, 07 Aug 2026 08:45:00 -0400 A.06822034 A.50216726 ATOS O.11433789 O.20026344 O.21612337 http://www.streetinsider.com/PRNewswire/Atossa+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+a+Corporate+Update/26888131.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.wa.seatle" idsrc="xmltag.org" >SEATTLE</location></span>, <span class="legendSpanClass"><chron>Aug. 7, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-SMALL:ATOS" idsrc="xmltag.org" >Atossa Therapeutics, Inc.</span> (Nasdaq: ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet clinical need, today announced its financial results and provided an update on recent corporate developments for the second quarter ended <chron>June 30, 2026</chron>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/Atossa+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+a+Corporate+Update/26888131.html Fri, 07 Aug 2026 08:45:00 -0400 A.06822034 A.50216726 ATOS O.11433789 O.20026344 O.21612337 http://www.streetinsider.com/PRNewswire/Atossa+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+a+Corporate+Update/26888131.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.wa.seatle" idsrc="xmltag.org" >SEATTLE</location></span>, <span class="legendSpanClass"><chron>Aug. 7, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-SMALL:ATOS" idsrc="xmltag.org" >Atossa Therapeutics, Inc.</span> (Nasdaq: ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet clinical need, today announced its financial results and provided an update on recent corporate developments for the second quarter ended <chron>June 30, 2026</chron>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/Atossa+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+a+Corporate+Update/26888131.html Fri, 07 Aug 2026 08:45:00 -0400 A.06822034 A.50216726 ATOS O.11433789 O.20026344 O.21612337 http://www.streetinsider.com/PRNewswire/Atossa+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+a+Corporate+Update/26888131.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.wa.seatle" idsrc="xmltag.org" >SEATTLE</location></span>, <span class="legendSpanClass"><chron>Aug. 7, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-SMALL:ATOS" idsrc="xmltag.org" >Atossa Therapeutics, Inc.</span> (Nasdaq: ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet clinical need, today announced its financial results and provided an update on recent corporate developments for the second quarter ended <chron>June 30, 2026</chron>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/Atossa+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+a+Corporate+Update/26888131.html Fri, 07 Aug 2026 08:45:00 -0400 A.06822034 A.50216726 ATOS O.11433789 O.20026344 O.21612337 http://www.streetinsider.com/PRNewswire/Atossa+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+a+Corporate+Update/26888131.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.wa.seatle" idsrc="xmltag.org" >SEATTLE</location></span>, <span class="legendSpanClass"><chron>Aug. 7, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-SMALL:ATOS" idsrc="xmltag.org" >Atossa Therapeutics, Inc.</span> (Nasdaq: ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet clinical need, today announced its financial results and provided an update on recent corporate developments for the second quarter ended <chron>June 30, 2026</chron>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/Atossa+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+a+Corporate+Update/26888131.html Fri, 07 Aug 2026 08:45:00 -0400 A.06822034 A.50216726 ATOS O.11433789 O.20026344 O.21612337 http://www.streetinsider.com/PRNewswire/Atossa+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+a+Corporate+Update/26888131.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.wa.seatle" idsrc="xmltag.org" >SEATTLE</location></span>, <span class="legendSpanClass"><chron>Aug. 7, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-SMALL:ATOS" idsrc="xmltag.org" >Atossa Therapeutics, Inc.</span> (Nasdaq: ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet clinical need, today announced its financial results and provided an update on recent corporate developments for the second quarter ended <chron>June 30, 2026</chron>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/Atossa+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+a+Corporate+Update/26888131.html Fri, 07 Aug 2026 08:45:00 -0400 A.06822034 A.50216726 ATOS O.11433789 O.20026344 O.21612337 http://www.streetinsider.com/PRNewswire/Atossa+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+a+Corporate+Update/26888131.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.wa.seatle" idsrc="xmltag.org" >SEATTLE</location></span>, <span class="legendSpanClass"><chron>Aug. 7, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-SMALL:ATOS" idsrc="xmltag.org" >Atossa Therapeutics, Inc.</span> (Nasdaq: ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet clinical need, today announced its financial results and provided an update on recent corporate developments for the second quarter ended <chron>June 30, 2026</chron>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/Atossa+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+a+Corporate+Update/26888131.html Fri, 07 Aug 2026 08:45:00 -0400 A.06822034 A.50216726 ATOS O.11433789 O.20026344 O.21612337 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++ATOSSA+THERAPEUTICS%2C++++++For%3A+Aug+07/26888136.html si-local-file:///var/storage/secattach/20260807/26888136.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++ATOSSA+THERAPEUTICS%2C++++++For%3A+Aug+07/26888136.html Fri, 07 Aug 2026 08:45:00 -0400 ATOS O.11433789 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++ATOSSA+THERAPEUTICS%2C++++++For%3A+Aug+07/26888136.html si-local-file:///var/storage/secattach/20260807/26888136.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++ATOSSA+THERAPEUTICS%2C++++++For%3A+Aug+07/26888136.html Fri, 07 Aug 2026 08:45:00 -0400 ATOS O.11433789 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++ATOSSA+THERAPEUTICS%2C++++++For%3A+Jun+30/26888059.html si-local-file:///var/storage/secattach/20260807/26888059.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++ATOSSA+THERAPEUTICS%2C++++++For%3A+Jun+30/26888059.html Fri, 07 Aug 2026 08:30:00 -0400 ATOS O.11433789 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++ATOSSA+THERAPEUTICS%2C++++++For%3A+Jun+30/26888059.html si-local-file:///var/storage/secattach/20260807/26888059.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++ATOSSA+THERAPEUTICS%2C++++++For%3A+Jun+30/26888059.html Fri, 07 Aug 2026 08:30:00 -0400 ATOS O.11433789 http://www.streetinsider.com/Corporate+News/Atossa+preclinical+study+on+endoxifen+compounds+published+in+npj/26823055.html <p>Atossa Therapeutics (NASDAQ: ATOS) announced the publication of a peer-reviewed preclinical study in <em>npj Breast Cancer</em> evaluating five novel chemical entities structurally related to (Z)-endoxifen, conducted in collaboration with Mayo Clinic.</p><p>The study, published July 20, 2026, assessed compounds AT416E, AT416Z, AT402E, AT402Z, and AT300 across a range of laboratory assays, including two- and three-dimensional tumor-cell growth, apoptosis, cell-cycle progression, migration, invasion, and estrogen receptor transcriptional activity.</p><p>Several compounds showed anti-estrogenic effects in estrogen receptor-positive breast cancer models, including models with activating ESR1 mutations, which are associated with endocrine resistance in advanced disease. In certain experimental conditions, selected compounds combined with the http://www.streetinsider.com/Corporate+News/Atossa+preclinical+study+on+endoxifen+compounds+published+in+npj/26823055.html Tue, 28 Jul 2026 08:30:55 -0400 ATOS http://www.streetinsider.com/FDA/Atossa+preclinical+study+on+endoxifen+compounds+published+in+npj/26823055.html <p>Atossa Therapeutics (NASDAQ: ATOS) announced the publication of a peer-reviewed preclinical study in <em>npj Breast Cancer</em> evaluating five novel chemical entities structurally related to (Z)-endoxifen, conducted in collaboration with Mayo Clinic.</p><p>The study, published July 20, 2026, assessed compounds AT416E, AT416Z, AT402E, AT402Z, and AT300 across a range of laboratory assays, including two- and three-dimensional tumor-cell growth, apoptosis, cell-cycle progression, migration, invasion, and estrogen receptor transcriptional activity.</p><p>Several compounds showed anti-estrogenic effects in estrogen receptor-positive breast cancer models, including models with activating ESR1 mutations, which are associated with endocrine resistance in advanced disease. In certain experimental conditions, selected compounds combined with the http://www.streetinsider.com/FDA/Atossa+preclinical+study+on+endoxifen+compounds+published+in+npj/26823055.html Tue, 28 Jul 2026 08:30:55 -0400 ATOS http://www.streetinsider.com/Press+Releases/Atossa+Therapeutics+Announces+Publication+of+Novel+%28Z%29-Endoxifen-Related+Compounds+Demonstrating+Potent+Anti-Cancer+Activity+in+ER-Positive+Breast+Cancer/26823012.html <div class="xn-content"> <p class="prntac"><i>Peer-reviewed preclinical study published in npj Breast Cancer identifies new chemical entities with activity in ESR1-mutant models </i></p><p class="prntac"><i>Findings suggest potential for combination with abemaciclib</i></p><p><span class="legendSpanClass"><location value="LU/us.wa.seatle" idsrc="xmltag.org" >SEATTLE</location></span>, <span class="legendSpanClass"><chron>July 28, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-SMALL:ATOS" idsrc="xmltag.org" >Atossa Therapeutics, Inc.</span> (NASDAQ: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of significant unmet clinical need, today announced the publication of a peer-reviewed preclinical study in npj Breast Cancer evaluating five novel chemical entities structurally related to (Z)-endoxifen. The study titled, "Novel (Z)-endoxifen-related new chemical entities exhibit potent anti-cancer activity http://www.streetinsider.com/Press+Releases/Atossa+Therapeutics+Announces+Publication+of+Novel+%28Z%29-Endoxifen-Related+Compounds+Demonstrating+Potent+Anti-Cancer+Activity+in+ER-Positive+Breast+Cancer/26823012.html Tue, 28 Jul 2026 08:30:00 -0400 A.07309385 ATOS O.11433789 O.20043539 http://www.streetinsider.com/Press+Releases/Atossa+Therapeutics+Announces+Publication+of+Novel+%28Z%29-Endoxifen-Related+Compounds+Demonstrating+Potent+Anti-Cancer+Activity+in+ER-Positive+Breast+Cancer/26823012.html <div class="xn-content"> <p class="prntac"><i>Peer-reviewed preclinical study published in npj Breast Cancer identifies new chemical entities with activity in ESR1-mutant models </i></p><p class="prntac"><i>Findings suggest potential for combination with abemaciclib</i></p><p><span class="legendSpanClass"><location value="LU/us.wa.seatle" idsrc="xmltag.org" >SEATTLE</location></span>, <span class="legendSpanClass"><chron>July 28, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-SMALL:ATOS" idsrc="xmltag.org" >Atossa Therapeutics, Inc.</span> (NASDAQ: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of significant unmet clinical need, today announced the publication of a peer-reviewed preclinical study in npj Breast Cancer evaluating five novel chemical entities structurally related to (Z)-endoxifen. The study titled, "Novel (Z)-endoxifen-related new chemical entities exhibit potent anti-cancer activity http://www.streetinsider.com/Press+Releases/Atossa+Therapeutics+Announces+Publication+of+Novel+%28Z%29-Endoxifen-Related+Compounds+Demonstrating+Potent+Anti-Cancer+Activity+in+ER-Positive+Breast+Cancer/26823012.html Tue, 28 Jul 2026 08:30:00 -0400 A.07309385 ATOS O.11433789 O.20043539 http://www.streetinsider.com/Press+Releases/Atossa+Therapeutics+Announces+Publication+of+Novel+%28Z%29-Endoxifen-Related+Compounds+Demonstrating+Potent+Anti-Cancer+Activity+in+ER-Positive+Breast+Cancer/26823012.html <div class="xn-content"> <p class="prntac"><i>Peer-reviewed preclinical study published in npj Breast Cancer identifies new chemical entities with activity in ESR1-mutant models </i></p><p class="prntac"><i>Findings suggest potential for combination with abemaciclib</i></p><p><span class="legendSpanClass"><location value="LU/us.wa.seatle" idsrc="xmltag.org" >SEATTLE</location></span>, <span class="legendSpanClass"><chron>July 28, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-SMALL:ATOS" idsrc="xmltag.org" >Atossa Therapeutics, Inc.</span> (NASDAQ: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of significant unmet clinical need, today announced the publication of a peer-reviewed preclinical study in npj Breast Cancer evaluating five novel chemical entities structurally related to (Z)-endoxifen. The study titled, "Novel (Z)-endoxifen-related new chemical entities exhibit potent anti-cancer activity http://www.streetinsider.com/Press+Releases/Atossa+Therapeutics+Announces+Publication+of+Novel+%28Z%29-Endoxifen-Related+Compounds+Demonstrating+Potent+Anti-Cancer+Activity+in+ER-Positive+Breast+Cancer/26823012.html Tue, 28 Jul 2026 08:30:00 -0400 A.07309385 ATOS O.11433789 O.20043539 http://www.streetinsider.com/Press+Releases/Atossa+Therapeutics+Announces+Publication+of+Novel+%28Z%29-Endoxifen-Related+Compounds+Demonstrating+Potent+Anti-Cancer+Activity+in+ER-Positive+Breast+Cancer/26823012.html <div class="xn-content"> <p class="prntac"><i>Peer-reviewed preclinical study published in npj Breast Cancer identifies new chemical entities with activity in ESR1-mutant models </i></p><p class="prntac"><i>Findings suggest potential for combination with abemaciclib</i></p><p><span class="legendSpanClass"><location value="LU/us.wa.seatle" idsrc="xmltag.org" >SEATTLE</location></span>, <span class="legendSpanClass"><chron>July 28, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-SMALL:ATOS" idsrc="xmltag.org" >Atossa Therapeutics, Inc.</span> (NASDAQ: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of significant unmet clinical need, today announced the publication of a peer-reviewed preclinical study in npj Breast Cancer evaluating five novel chemical entities structurally related to (Z)-endoxifen. The study titled, "Novel (Z)-endoxifen-related new chemical entities exhibit potent anti-cancer activity http://www.streetinsider.com/Press+Releases/Atossa+Therapeutics+Announces+Publication+of+Novel+%28Z%29-Endoxifen-Related+Compounds+Demonstrating+Potent+Anti-Cancer+Activity+in+ER-Positive+Breast+Cancer/26823012.html Tue, 28 Jul 2026 08:30:00 -0400 A.07309385 ATOS O.11433789 O.20043539 http://www.streetinsider.com/PRNewswire/Atossa+Therapeutics+Announces+Publication+of+Novel+%28Z%29-Endoxifen-Related+Compounds+Demonstrating+Potent+Anti-Cancer+Activity+in+ER-Positive+Breast+Cancer/26823012.html <div class="xn-content"> <p class="prntac"><i>Peer-reviewed preclinical study published in npj Breast Cancer identifies new chemical entities with activity in ESR1-mutant models </i></p><p class="prntac"><i>Findings suggest potential for combination with abemaciclib</i></p><p><span class="legendSpanClass"><location value="LU/us.wa.seatle" idsrc="xmltag.org" >SEATTLE</location></span>, <span class="legendSpanClass"><chron>July 28, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-SMALL:ATOS" idsrc="xmltag.org" >Atossa Therapeutics, Inc.</span> (NASDAQ: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of significant unmet clinical need, today announced the publication of a peer-reviewed preclinical study in npj Breast Cancer evaluating five novel chemical entities structurally related to (Z)-endoxifen. The study titled, "Novel (Z)-endoxifen-related new chemical entities exhibit potent anti-cancer activity http://www.streetinsider.com/PRNewswire/Atossa+Therapeutics+Announces+Publication+of+Novel+%28Z%29-Endoxifen-Related+Compounds+Demonstrating+Potent+Anti-Cancer+Activity+in+ER-Positive+Breast+Cancer/26823012.html Tue, 28 Jul 2026 08:30:00 -0400 A.07309385 ATOS O.11433789 O.20043539 http://www.streetinsider.com/PRNewswire/Atossa+Therapeutics+Announces+Publication+of+Novel+%28Z%29-Endoxifen-Related+Compounds+Demonstrating+Potent+Anti-Cancer+Activity+in+ER-Positive+Breast+Cancer/26823012.html <div class="xn-content"> <p class="prntac"><i>Peer-reviewed preclinical study published in npj Breast Cancer identifies new chemical entities with activity in ESR1-mutant models </i></p><p class="prntac"><i>Findings suggest potential for combination with abemaciclib</i></p><p><span class="legendSpanClass"><location value="LU/us.wa.seatle" idsrc="xmltag.org" >SEATTLE</location></span>, <span class="legendSpanClass"><chron>July 28, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-SMALL:ATOS" idsrc="xmltag.org" >Atossa Therapeutics, Inc.</span> (NASDAQ: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of significant unmet clinical need, today announced the publication of a peer-reviewed preclinical study in npj Breast Cancer evaluating five novel chemical entities structurally related to (Z)-endoxifen. The study titled, "Novel (Z)-endoxifen-related new chemical entities exhibit potent anti-cancer activity http://www.streetinsider.com/PRNewswire/Atossa+Therapeutics+Announces+Publication+of+Novel+%28Z%29-Endoxifen-Related+Compounds+Demonstrating+Potent+Anti-Cancer+Activity+in+ER-Positive+Breast+Cancer/26823012.html Tue, 28 Jul 2026 08:30:00 -0400 A.07309385 ATOS O.11433789 O.20043539